Evidence map›Paper›PMID 40550315›Full record

ArticleSLAS discovery : advancing life sciences R & D2025

MT1G activation in dopaminergic neurons identifies chelators and their relationships to cytotoxicity.

Zhi-Bin Tong, Srilatha Sakamuru, James Travers, Tuan Xu, Shu Yang, Menghang Xia, Anton Simeonov, Ruili Huang, David Gerhold

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhi-Bin TongDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Srilatha SakamuruDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
James TraversDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Tuan XuDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Shu YangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Menghang XiaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Anton SimeonovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
Ruili HuangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850.
David GerholdDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Dr., Bldg C-345E, Rockville, MD 20850. Electronic address: david.gerhold@nih.gov.

Funding

Toxicology in the 21st Century Program (Tox21) - Genomic ToxicologyZIATR000039 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI GERHOLD, DAVID · 2016 to 2025
$5.1M
Toxicology in the 21st Century Program (Tox21) Genomic ToxicologyZICTR000039 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI GERHOLD, DAVID · 2015 to 2015
$100k
Intramural NIH HHS Z99 TR999999Intramural NIH HHS ZIA TR000039Intramural NIH HHS ZIC TR000039
6 · The paper itself

Abstract

Although multiple pesticides and solvents are risk factors for Parkinson's disease [1] and other neurodegenerative diseases, most risk factors remain undiscovered. We previously identified the metallothionein gene MT1G as a biomarker for neurotoxicity induced by all seven neurotoxicants tested in LUHMES dopaminergic neurons. Here we used CRISP/R technology to insert a HiBiT tag into the MT1G gene of the LUHMES cell line. The engineered LUHMES MT1G::HiBiT cell lines were used to develop a quantitative high throughput screening [2] assay in a 3D-suspension culture platform with 1536 well microplates. We validated this qHTS assay by screening the LOPAC (Library of Pharmacologically Active Compounds) collection composed of 1280 compounds plus 88 selected Tox21 chemicals, demonstrating high signal-to-noise and reproducibility. In screening this library, 49 compounds were confirmed to significantly increase MT1G-HiBiT activity, including 35 compounds that exhibited cytotoxicity below 50 μM, and 14 noncytotoxic compounds. Most of these MT1G-HiBiT inducers killed cells at concentrations moderately higher than their MT1G-HiBiT activation potencies (AC

Indexed as

Chelating AgentsDopaminergic NeuronsMetallothioneinAnimalsCell LineCell SurvivalHigh-Throughput Screening AssaysHumansSmall Molecule LibrariesChelating AgentsMetallothioneinSmall Molecule LibrariesDopaminergic neuronsLUHMESMetallothioneinNeurotoxicityQuantitative high-throughput screening

Identifiers

PMID40550315
PMCPMC13472443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.